Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | CSF1R | P07333 | 1/20 | 0.42 |
| ▸ | KDM5A | P29375 | 1/20 | 0.41 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | ALPL | P05186 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5860089 | 0.80 | ALDH1A1 (0.49) | MAPTMEN1KMT2AALDH1A1PKM | |
| SCHEMBL5860143 | 0.77 | LMNA (0.49) | MAPTMEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL5860068 | 0.75 | TOP1 (0.43) | MAPTMEN1KMT2AHSD17B10ALDH1A1 | |
| SCHEMBL8805110 | 0.67 | ALDH1A1 (0.51) | MAPTMEN1KMT2AHSD17B10TSHR | |
| SCHEMBL7818198 | 0.67 | TSHR (0.66) | MAPTMEN1KMT2AHSD17B10TSHR | |
| SCHEMBL6295988 | 0.67 | ALDH1A1 (0.55) | MAPTMEN1KMT2AHSD17B10TSHR | |
| SCHEMBL5859825 | 0.67 | LMNA (0.50) | MAPTALDH1A1PKMKDM4EKDM5A | |
| SCHEMBL13739817 | 0.66 | CSF1R (0.52) | MAPTMEN1KMT2AHSD17B10TSHR | |
| SCHEMBL12492331 | 0.66 | KDM5A (0.54) | MAPTMEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL8142770 | 0.65 | KDM5A (0.62) | KDM5AKDM5B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1254908-B9 | Preparation of a camptothecin derivative by intramolecular cyclisation | OSI PHARM INC (US) | 2005-09-21 | — | — | EP | disclosed |
| EP-1254908-B1 | Preparation of a camptothecin derivative by intramolecular cyclisation | OSI PHARM INC (US) | 2005-02-23 | — | — | EP | disclosed |
| US-6821982-B2 | Preparation of a camptothecin derivative by intramolecular cyclisation | OSI PHARMACEUTICALS, INC. | 2004-11-23 | — | — | US | disclosed |
| EP-0758333-B1 | INTERMEDIATES IN PHARMACEUTICAL CAMPTOTHECIN PREPARATION | OSI PHARM INC (US) | 2004-03-03 | — | — | EP | disclosed |
| US-20030204088-A1 | Preparation of a camptothecin derivative by intramolecular cyclisation | OSI PHARMACEUTICALS, INC. | 2003-10-30 | — | — | US | disclosed |
| US-6559309-B2 | Preparation for camptothecin and camptothecin-like compounds and to novel intermediates used in this preparation. The process for the preparation of the camptothecin derivative known by 7-(4 | OSI PHARMACEUTICALS, INC. | 2003-05-06 | — | — | US | disclosed |
| US-20030045719-A1 | Preparation of a camptothecin derivative by intramolecular cyclisation | OSI PHARMACEUTICALS, INC. | 2003-03-06 | — | — | US | disclosed |
| EP-1254908-A1 | Preparation of a camptothecin derivative by intramolecular cyclisation | GILEAD SCIENCES, INC. (US) | 2002-11-06 | — | — | EP | disclosed |
| EP-0758335-B1 | PREPARATION OF A CAMPTOTHECIN DERIVATIVE BY INTRAMOLECULAR CYCLISATION | GILEAD SCIENCES INC (US) | 2002-11-06 | — | — | EP | disclosed |
| US-6462196-B1 | NOVEL INTERMEDIATES USED IN THE PREPARATION OF CAMPTOTHECIN DERIVATIVES | OSI PHARMACEUTICALS, INC. | 2002-10-08 | — | — | US | disclosed |
| US-6063923-A | Preparation of a camptothecin derivative by intramolecular cyclisation | GLAXO WELLCOME INC. (US) | 2000-05-16 | — | — | US | disclosed |
| EP-0758333-A1 | INTERMEDIATES IN PHARMACEUTICAL CAMPTOTHECIN PREPARATION | GLAXO WELLCOME INC. (US) | 1997-02-19 | — | — | EP | disclosed |
| WO-1995029917-A2 | INTERMEDIATES IN PHARMACEUTICAL CAMPTOTHECIN PREPARATION | GLAXO WELLCOME INC. (US) | 1995-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030204088-A1 | Preparation of a camptothecin derivative by intramolecular cyclisation | TOP1, TOP2A, TOP2B | MAPT 4732/4885MEN1 209/4885KMT2A 3974/4885 |
| US-20030045719-A1 | Preparation of a camptothecin derivative by intramolecular cyclisation | TOP1, TOP2A, TOP2B | MAPT 4679/4885MEN1 294/4885KMT2A 3970/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.